Prosecution Insights
Last updated: November 04, 2026
Application No. 17/351,160

VAPORIZER DEVICE AND METHOD FOR DELIVERING ACCURATE DOSE

Final Rejection §102§103
Filed
Jun 17, 2021
Priority
Mar 17, 2020 — provisional 62/990,769 +2 more
Examiner
CULBERT, COURTNEY GUENTHER
Art Unit
1747
Tech Center
1700 — Chemical & Materials Engineering
Assignee
The Green Labs Group Inc.
OA Round
4 (Final)
28%
Grant Probability
At Risk
5-6
OA Rounds
0m
Est. Remaining
32%
With Interview

Examiner Intelligence

Grants only 28% of cases
28%
Career Allowance Rate
15 granted / 54 resolved
-37.2% vs TC avg
Minimal +4% lift
Without
With
+4.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
63 currently pending
Career history
121
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
56.7%
+16.7% vs TC avg
§102
25.3%
-14.7% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 54 resolved cases

Office Action

§102 §103
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Status of the Claims Claims 1-22 are pending. Claims 15-20 are withdrawn. Claim 1 has been amended. Response to Amendments The Examiner acknowledges Applicant's response filed on 7/23/2026 containing amendments and Applicant's response filed on 3 remarks to the claims. Response to Arguments Applicant's arguments filed 3 have been fully considered but they are not persuasive. Applicant argues that the newly added limitation to claim 1 concerning the vapor correlation data comprising data correlating measured amounts of the active ingredient extracted during vaporization with corresponding values of the at least one vaporizer parameter refers to a “pre-established, empirically-driven dataset” (Remarks, Page 1). Specifically, “vapor samples are collected from the vaporizer device, laboratory-analyzed for active ingredient content . . . and correlated with the vaporizer’s operating parameters . . . using a machine learning module” (Remarks, Page 1). Applicant argues that “Anderson does not disclose any system for collecting vapor samples, measuring active ingredient quantities via laboratory analysis, and generated a correlated dataset” (Remarks, Page 2). This argument is not persuasive as claim 1 is directed to a product, not a method of manufacturing a product. As such, Anderson only needs to disclose the structure implied by the newly added limitations to claim 1 to anticipate the claim, not the specific process steps used to create the product (MPEP § 2113(I)). With regard to the structure of the vapor correlation data, claim 1 states that the vapor correlation data is stored in the electronic storage memory. Anderson also discloses that the vapor correlation data is stored in electronic storage memory (¶ 0265). As such, although the data by Anderson may not have been generated by a laboratory analysis processed through a machine learning module, Anderson still anticipates the structure implied by this limitation (data stored in electronic memory); therefore, Anderson anticipates the limitation. Applicant further argues that the relationship between the at least one vaporizer parameter and the dose in claim 1 is that the requested dose is used to determine, based on the vapor correlation data, the vaporizer parameter needed to achieve said dose. Applicant argues that Anderson does the opposite and “describes estimating the dose from known thermal properties” (Remarks, Page 2). This argument is not persuasive as Anderson does disclose the correct relationship required by claim 1; specifically, Anderson discloses determining the vaporizer parameter (the temperature) based on the desired dose (“the vaporizer device and/or the vaporizer system may adjust the temperature of the heater in accordance with the . . . dosage”, ¶ 0296). Applicant further argues that the cited portions of Anderson “use ‘may’ language, indicating optional speculative features”, and “[a]n optional disclosure that something ‘may’ be done does not establish that it is disclosed” (Remarks, Page 2). This argument is not persuasive as “alternative embodiments constitute prior art” (MPEP § 2123(II)). Applicant further argues that Anderson does not “control the at least one vaporizer parameter in real time during operation based on the determined value” because Anderson discloses using an inhalation detector, and “[p]uff detection—determining when to activate the heater—is not the same as controlling a vaporizer parameter in real time based on a dose-derived value” (Remarks, Page 2). This argument is not persuasive as Anderson discloses using an inhalation detector to control the moment (i.e., real time control) when the heating element needs to be raised to the desired temperature (“to reliably activate the heating element or heat the heating element to a desired temperature, a vaporizer may, in some implementations of the current subject matter, make use of signals from a pressure sensor to determine when a user is inhaling”, ¶ 0239), and the temperature, as discussed above, is a dose-derived value (see ¶ 0296). Applicant further argues that the rejection uses different paragraphs from the disclosure of Anderson “that address different features (user interface options, puff detection, cartridge information, temperature adjustment) in different contexts. These features are never disclosed as an integrated system operating in the manner required by claim 1” (Remarks, Page 3). This argument is not persuasive as the cited paragraphs of Anderson are an express contemplation of all of the elements of claim 1; as such, one having ordinary skill in the art would at once envisage the product of claim 1 (MPEP § 2131.02(III)). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-8, 10-14, and 21-22 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Anderson et al. (US 2020/0000143 A1). Regarding claim 1, Anderson discloses a vaporizer device (“vaporizer device 100”, Fig. 1, ¶ 0230) comprising: a receptacle for holding material having an active ingredient (“vaporizer cartridge 52”, Fig. 1, ¶ 0241, a “vaporizable material . . . can be provided within [the] cartridge, ¶ 0008, and the vaporizable material comprises “active ingredients”, ¶ 0013); a heating element for heating the receptacle (“The vaporizer cartridge can include . . . a heating element”, ¶ 0241); an electronic storage memory (“memory”, ¶ 0265) for storing vapor correlation data (“Information about the . . . vaporizable material held in the cartridge”, ¶ 0265) including instructions configured to correlate dosage of the active ingredient (“the thermal properties of the vaporizable material, etc. may be used to accurately estimate dose”, ¶ 0265) with at least one vaporizer parameter (the vaporizer parameter being the temperature of the heater, “the vaporizer device and/or the vaporizer system may adjust the temperature of the heater in accordance with the . . . dosage”, ¶ 0296); and a controller (“controller 24”, Fig. 1, ¶ 0277) configured to: receive a user-specified requested dose of the active ingredient (“a user may enter a preferred unit dose”, ¶ 0562); access the vapor correlation data to determine a value of the at least one vaporizer parameter required to achieve the requested dose based on the correlation data (“the thermal properties of the vaporizable material, etc. may be used to accurately estimate dose”, ¶ 0265, and “the vaporizer device and/or the vaporizer system may adjust the temperature of the heater in accordance with the . . . dosage”, ¶ 0296); and control the at least one vaporizer parameter in real time during operation based on the determined value (“to reliably activate the heating element or heat the heating element to a desired temperature, a vaporizer may, in some implementations of the current subject matter, make use of signals from a pressure sensor to determine when a user is inhaling”, ¶ 0239), the control of the at least one vaporizer parameter modifies the operation of the vaporizer device to produce a vapor from heating and emit the requested dose from the vaporizer device (“detection by the computing device of user interaction with one or more user interface elements can cause the computing device to signal the vaporizer device 100 to activate the heating element, either to a full operating temperature for creation of an inhalable dose of vapor/aerosol”, ¶ 0238). With regards to the vapor correlation data correlating measured amounts of the active ingredient extracted during vaporization with corresponding values of the at least one vaporizer parameter, this limitation refers to how the data was generated prior to being stored in the electronic storage memory, i.e., the limitation refers to the process by which the product was made. However, as Anderson discloses the resulting product, Anderson anticipates the claim, even if made by a different process (MPEP § 2113(I)). Regarding claim 2, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses a user interface (“user interface”, ¶ 0544) for entering the requested dose of active ingredient (¶ 0544). Regarding claim 3, Anderson discloses the vaporizer device of claim 2, as discussed above. Anderson further discloses communications circuitry (“communications hardware 34”, Fig. 1, ¶ 0255), wherein the user interface is a connected software application on a mobile device that is communicatively coupled to the controller via the communications circuitry (“a computing device used as part of a vaporizer system may include a general-purpose computing device (e.g., a smartphone, a tablet, a personal computer, some other portable device such as a smartwatch, or the like) that executes software to produce a user interface for enabling a user of the device to interact with a vaporizer”, ¶ 0236). Regarding claim 4, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses wherein the controller is configured to calculate an available dose of active ingredient using the vapor correlation data (“the quantity of vaporizable material remaining in the cartridge may be determined by at least reading an identifier associated with the cartridge”, ¶ 0040). Regarding claim 5, Anderson discloses the vaporizer device of claim 3, as discussed above. Anderson further discloses wherein the connected software application on the mobile device is configured to calculate an available dose of active ingredient using the vapor correlation data (“the quantity of vaporizable material remaining in the cartridge may be determined by at least reading an identifier associated with the cartridge”, ¶ 0040, and “A computing device that is part of a vaporizer system as defined above can be used for any of one or more functions, such as controlling dosing (e.g., dose monitoring, dose setting, dose limiting, user tracking, etc.)”, ¶ 0237). Regarding claim 6, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses sensors (“sensors 32”, Fig. 1, ¶ 0235) configured to provide vapor production data (“detection of the puff”, ¶ 0235), the sensors comprising a vapor flow rate sensor (“flow sensors of the vaporizer”, ¶ 0235). Regarding claim 7, Anderson discloses the vaporizer device of claim 6, as discussed above. Anderson further discloses wherein the controller is configured to calculate an available dose of active ingredient from the vapor correlation data and from the vapor production data from a previous vaporization session using the material (Anderson discloses that the “number of puffs” can be “used to estimate the amount of vaporizable material that has been removed from the cartridge” (i.e., vapor production data from a previous vaporization session), ¶ 0327, which when combined with the vapor correlation data which contained the original amount of vaporizable material in the cartridge, ¶ 0040, allows for a calculation of the “the amount of vaporizable material remaining”, ¶ 0327). Regarding claim 8, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses wherein the vapor correlation data is received from a vaporizer profile management system (“The information retrieved from the pod . . . may be included in a user profile”, ¶ 0279). Regarding claim 10, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses wherein the active ingredient is nicotine (“the vaporizable material a solution of nicotine, cannabis, and/or another active ingredient”, ¶ 0223). Regarding claim 11, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses wherein the vapor correlation data comprises a sample identifier that is associated with a material having the active ingredient (“The method may further include determining the flavor, the concentration, and/or the quantity of vaporizable material remaining in the cartridge by at least reading an identifier associated with the cartridge”, ¶ 0048). Regarding claim 12, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses communication circuitry (“communications hardware 34”, Fig. 1, ¶ 0255) comprising at least a wireless communication interface (“wireless”, ¶ 0255). Regarding claim 13, Anderson discloses the vaporizer device of claim 12, as discussed above. Anderson further discloses wherein the wireless communication interface comprises Bluetooth (“Bluetooth”, ¶ 0255). Regarding claim 14, Anderson discloses the vaporizer device of claim 8, as discussed above. Anderson further discloses wherein the vaporizer profile management system is hosted on a remote cloud computing platform (“it may communicate with a remote server that may look up the properties and communicate them to the vaporizer directly or through the smartphone”, ¶ 0261). Regarding claim 21, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses wherein the vaporizer parameter includes a temperature (“temperature of the heater”, ¶ 0296). Regarding claim 22, Anderson discloses the vaporizer device of claim 1, as discussed above. Anderson further discloses wherein the vaporizer parameter includes a physical property of the receptacle (“temperature of the heater”, ¶ 0296). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Anderson et al. (US 2020/0000143 A1) as applied to claim 1 above, and further in view of Blackley (US 2016/0370337 A1). Regarding claim 9, Anderson discloses the vaporizer device of claim 1, as discussed above. However, Anderson does not disclose wherein the vapor correlation data is downloaded from a vapor profile management system as a subscription service. Blackley, in the same field of endeavor, discloses downloading data from a vaporizer profile management system as a subscription service (“the computing device . . . can communicated with the user device . . . for providing data/and or services . . . . The computing device . . . can combine the content from multiple sources and can distribute the content to the user (e.g., subscriber)”, ¶ 0139). One of ordinary skill in the art would have understood that there was a benefit to configuring the device to download vapor correlation data from a vaporizer profile management system as a subscription service in that it provides additional revenue. Therefore, it would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to have the vapor correlation data be downloaded from a vaporizer profile management system as a subscription service in order to obtain this benefit. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to COURTNEY G CULBERT whose telephone number is (571)270-0874. The examiner can normally be reached Monday-Friday 9am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael H Wilson can be reached at (571)270-3882. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.G.C./Examiner, Art Unit 1747 /Michael H. Wilson/Supervisory Patent Examiner, Art Unit 1747
Read full office action

Prosecution Timeline

Show 5 earlier events
Apr 17, 2025
Final Rejection mailed — §102, §103
Jun 17, 2025
Response after Non-Final Action
Jul 16, 2025
Request for Continued Examination
Jul 19, 2025
Response after Non-Final Action
Oct 01, 2025
Non-Final Rejection mailed — §102, §103
Mar 31, 2026
Response Filed
Mar 31, 2026
Response after Non-Final Action
Oct 07, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12757927
SMOKING ARTICLE COMPRISING NOVEL FLAVORING AGENT
3y 5m to grant Granted Oct 13, 2026
Patent 12690618
ELECTRONIC ATOMIZATION DEVICE AND ATOMIZER AND SEALING STRUCTURE THEREOF, AND ATOMIZER ASSEMBLING METHOD
4y 8m to grant Granted Jul 28, 2026
Patent 12582162
NICOTINE POD ASSEMBLIES AND NICOTINE E-VAPING DEVICES
3y 4m to grant Granted Mar 24, 2026
Patent 12582163
NON-NICOTINE POD ASSEMBLIES AND NON-NICOTINE E-VAPING DEVICES
3y 4m to grant Granted Mar 24, 2026
Patent 12575607
NON-NICOTINE POD ASSEMBLIES AND NON-NICOTINE E-VAPING DEVICES
3y 1m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
28%
Grant Probability
32%
With Interview (+4.3%)
3y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 54 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month